Showing results (71-80 of 99) with videos related to

Sort By:
Pageof 10
International Journal of Cardiology. Heart & Vasculature|September 18, 2020
Scaffold underexpansion and late lumen loss after bioresorbable scaffold implantation: Insights from ABSORB JAPAN trialKozo Okada, Yasuhiro Honda, Hideki Kitahara, et al.
Journal of the American College of Cardiology|December 15, 2010
Outcomes in diabetic and nondiabetic patients treated with everolimus- or paclitaxel-eluting stents: results from the SPIRIT IV clinical trial (Clinical Evaluation of the XIENCE V Everolimus Eluting Coronary Stent System)Dean J Kereiakes, Donald E Cutlip, Robert J Applegate, et al.
JACC. Cardiovascular Interventions|April 7, 2018
Bioresorbable Scaffold for Treatment of Coronary Artery Lesions: Intravascular Ultrasound Results From the ABSORB Japan TrialKozo Okada, Yasuhiro Honda, Hideki Kitahara, et al.
The American Journal of Cardiology|January 21, 2011
Long-term (three-year) safety and efficacy of everolimus-eluting stents compared to paclitaxel-eluting stents (from the SPIRIT III Trial)Robert J Applegate, Manejeh Yaqub, James B Hermiller, et al.
The New England Journal of Medicine|May 7, 2010
Everolimus-eluting versus paclitaxel-eluting stents in coronary artery diseaseGregg W Stone, Ali Rizvi, William Newman, et al.
Catheterization and Cardiovascular Interventions : Official Journal of the Society for Cardiac Angiography & Interventions|November 23, 2012
Clinical outcomes in real-world patients with acute myocardial infarction receiving XIENCE V® everolimus-eluting stents: one-year results from the XIENCE V USA studyKrishnankutty Sudhir, James B Hermiller, Srihari S Naidu, et al.
Eurointervention : Journal of Europcr in Collaboration with the Working Group on Interventional Cardiology of the European Society of Cardiology|April 29, 2014
The ABSORB EXTEND study: preliminary report of the twelve-month clinical outcomes in the first 512 patients enrolledAlexandre Abizaid, J Ribamar Costa, Antonio L Bartorelli, et al.
JACC. Cardiovascular Interventions|November 26, 2011
Impact of lesion length and vessel size on clinical outcomes after percutaneous coronary intervention with everolimus- versus paclitaxel-eluting stents pooled analysis from the SPIRIT (Clinical Evaluation of the XIENCE V Everolimus Eluting Coronary Stent System) and COMPARE (Second-generation everolimus-eluting and paclitaxel-eluting stents in real-life practice) Randomized TrialsBimmer E Claessen, Pieter C Smits, Dean J Kereiakes, et al.
JACC. Cardiovascular Interventions|September 21, 2013
Meta-analysis of everolimus-eluting versus paclitaxel-eluting stents in coronary artery disease: final 3-year results of the SPIRIT clinical trials program (Clinical Evaluation of the Xience V Everolimus Eluting Coronary Stent System in the Treatment of Patients With De Novo Native Coronary Artery Lesions)George D Dangas, Patrick W Serruys, Dean J Kereiakes, et al.
Circulation. Cardiovascular Interventions|May 6, 2015
Stent Thrombosis and Dual Antiplatelet Therapy Interruption With Everolimus-Eluting Stents: Insights From the Xience V Coronary Stent System TrialsPhilippe Généreux, David R Rutledge, Tullio Palmerini, et al.
Pageof 10